TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
A phase 1/2 trial of Vepdegestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.
Overview
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) is a phase 1/2 interventional study registered as NCT06125522 by Pfizer, with 11 participants enrolled, started 2024-01-10 and due to reach its primary completion in 2026-12-31. Interventions recorded: vepdegestrant and Samuraciclib.
Similar pages
not linked directly; found by shared links- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Vepdegestrant, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Shares Vepdegestrant, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Shares Vepdegestrant, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Shares Vepdegestrant, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.